ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Patients with CP-CML who become resistant to a second-generation BCR::ABL1 TKI, either with or without a BCR::ABL1 gene mutation, generally experience low response rates and poor survival if treated with another second-generation TKI [8, 9].